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1. Introduction 
The striking analogies between the processes regula- 
ting secretion and contraction led Douglas and Rubin 
[l] to introduce the term ‘stimulus-secretion coupling’ 
to parallel the concept of ‘excitation-contraction 
coupling’ proposed earlier by Sandow [2] . The effects 
of several alkaloids on muscle contraction have long 
been recognized and their site and mechanism of
action extensively studied [3]. Among these alkaloids, 
methylxanthines are well-known potentiators of 
contraction [4] and, more recently, have been shown 
to increase secretion in various glands, in particular 
insulin release [5-71. The effects of quinine and of its 
optical isomer quinidine on contraction are, in some 
respects, imilar to those of methylxanthines, but are 
more complex, depending on the concentration used 
and on the type of muscle. As no attention has been 
paid on possible modifications of secretion by these 
latter alkaloids, we investigated the action of quinine 
on isolated islets of Langerhans. In this report, we 
show that the drug stimulates, potentiates or inhibits 
insulin release according to the experimental conditions 
and also alters glucose metabolism by islet cells. 
2. Materials and methods 
All experiments were performed with islets of 
Langerhans i olated by collagenase digestion [8] of 
the pancreas of fed male Wistar R rats (Mol, Belgium) 
weighing 275-300 g. The medium utilized was a 
Krebs-Ringer bicarbonate buffer (KRB), pH 7.4, 
280 
gassed with 02 /CO2 (94/6) and supplemented witl. 
0.5% (w/v) bovine serum albumin. 
2.1. Insulin release 
Insulin secretion was studied either in static incuba- 
tions carried out for 60 rnin in a shaking incubator or 
in a perifusion system that particularizes the dynamics 
of release [9,10]. Specific experimental conditions are 
given in the legends. Immunoreactive insulin (IRI) was 
measured by a double antibody assay [1 l] with rat 
insulin (21 IU/mg) as standard. No interference of the 
substances studied could be detected. 
2.2. Glucose metabolism 
Glucose oxidation by islet cells was measured as 
the formation of l4 COZ from D[U-14C]glucose. 
Batches of 10 islets were incubated, for 2 h at 37°C 
in 50 ~1 KRB contained in small polyethylene tubes 
suspended in glass counting vials that were tightly 
stoppered after being gassed. Metabolism was arrested 
by injection, through the stopper, of 10 ~1 1 N HCl 
into the polyethylene tube and CO? was collected 
during 4 h in 0.5 ml Hyamine injected in the vial. 
Glucose utilization was measured as the formation 
of [3H] water from D- [5-3H] glucose [121. Batches of 
10 islets were incubated in 20 fi KRB in the same 
conditions as described above. Metabolism was arrest- 
ed by injection of 10 ~1 0.2 N HCl, and [3 H] water 
formed was allowed to equilibrate overnight with 
0.5 ml water contained in the counting vial. 
Incubations without islets provided blank values 
for all experimental conditions. Samples of incubation 
media were used as external standards to translate the 
observed counts (after blank substraction) into 
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picomoles of glucose oxidized or utilized/hour/islet 
1121. 
2.3. Chemicals 
Quinine hydrochloride was from Sigma Co. (St 
Louis, USA); D-glucose and atropine sulfate from 
Merck, A. G. (Darmstadt, Germany); D-[U-14C]gluco- 
se (283 mCi/mmol) and D [ 5-3 H] glucose (1 Ci/mmol) 
from the Radiochemical Centre (Amersham, England), 
Hyamine hydroxide from Packard Instrument Co. 
(Downers Grove, USA). 
3. Results 
3.1. Insulin release 
As shown in fig.1, quinine exerted a dual effect on 
glucose-induced IRI release. Low concentrations of
the alkaloid (5 to 100 PM) potentiated the insulino- 
tropic action of the sugar. 50 PM quinine increased 
the amount of IRI released by more than 12 times in 
the presence of 100 mg glucose/l00 ml and by 1.8 
times at glucose 300 mg/lOO ml. By contrast, 0.5 and 
1 mM quinine markedly depressed the effect of the 
highest concentration of the sugar. In the absence of 
glucose, IRI release was significantly augmented 
0, < 0.001) from 0.44 rt 0.05 to 0.91 * 0.06 and 
1.2’7 f 0.09 n&let/60 min (n= 12) by 25 and 100 I.IM 
quinine, respectively. 
The possibility that quinine unspecitically aug- 
mented &cell membrane permeability and caused 
passive leakage of insulin could be ruled out by 
experiments carried out at low temperature. Table 1 
demonstrates that, at 22”C, glucose failed to stimulate 
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Fig.1. Effect of quinine on glucose-induced IRI release. After 
preincubation for 15 min in KRB containing 50 mg glucose/ 
100 ml, batches of 3 islets were transferred into 1 ml medium 
supplemented with various concentrations of quinine and 
glucose 100 mg/lOO ml (broken line) or 300 mg/lOO ml 
(solid line). IRI was measured in an ahquot of medium taken 
at the end of the 60 min of incubation at 37°C. Values are 
means f SEM of 12 observations. The significance of 
difference between experimental groups and controls without 
quinine is denoted by o = p > 0.05, o = p < 0.05 and l = 
p < 0.001. 
Table 1 
Effect of quinine on glucose-induced insulin release at 37°C and 22°C 
Glucose IRI released after 60 min of incubation (r&islet) 
concentration 
(mg/lOO ml) No Quinine Quinine (25 PM) 
100 
300 
37°C 22°C 37OC 22°C 
1.28 +_ 0.12 0.78 f O.lOa 10.52 f 0.94b 0.68 f 0.09 
26.11 f 1.16 0.89 f O.OPa 38.74 * 2.11b 0.93 * 0.08 
Values are means f SEM of 12 observations. Significance levels: a = p < 0.001 for 
difference from appropriate control at 37’C; b = p < 0.001 for difference from appro- 
priate control without quinine. Experimental conditions were similar to those describ- 
ed in fig. 1, except for temperature of incubation. 
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Fig.2. Reversibility of the inhibitory effect of 1 mM quinine on glucose-induced IRI release. Pools of 20 islets were perifused in 
parallel chambers with KRB containing 50 mg glucose/l00 ml from min -25 to 0. At min 0, glucose concentration was suddenly 
increased to 300 ms/lOO ml and maintained at this level until the end of the perifusion. The experimental group of islets (o-o) 
was further exposed to 1 mM quinine between min 15 and 30. Values are means + SEM of 5 experiments. 
Table 2 
Effect of quinine on glucose metabolism by islet cells 
Quinine Glucose oxidized (pmol/hr/isletl Glucose utilized (pmol/hr/islet) 
concentration 
(& Glucose 100 mg/lOO ml Glucose 300 mg/lOO ml Glucose 100 mg/lOO ml Glucose 300 mg/lOO ml 
0 20.21 + 1.06 41.47 f 3.63 47.65 * 1.45 100.08 + 3.50 
(101 (8) (10) (161 
50 19.88 + 1.02 39.15 * 3.31 47.36 f 1.67 94.03 k 2.00 
(10) (91 (101 (8) 
500 17.30 f 0.82a 39.36 f 2.81 41.96 * 1.05a 96.43 + 4.63 
(101 (9) (10) (81 
1000 5.75 + 0.36b 7.31 r 0.48b 25.06 +- 1.27b 48.50 f 4.25b 
(10) (91 (101 (81 
After 15 min of preincubation in the absence of glucose, islets were incubated as described in the section ‘Materials and methods’. 
To the incubation media were added 1 rCi D-l-U-“C]glucose/SO-Al KRB and 0.1 &i D[-5-3H]glucose/20 pl KRB, respectively 
for oxidation and utilization measurements. 
Values are means f SEM of the number of observations indicated in parentheses. Significance levels : a = p< 0.05 and b = 
p< 0.001 for difference from appropriate control without quinine. 
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1 ,uM atropine, a concentration higher than that 
required to block the effect of acetylcholine in the 
islets [ 13,141, did not alter the potentiation by 25 
PM quinine of IRI releaseinduced by 100 g glucose/ 
100 ml (13.37 + 0.86 and 13.60 + 0.59 ng/islet/60 min, 
n = 16, without and with atropine). 
The dynamics and the reversibility of quinine-induc- 
ed inhibition of IRI release are illustrated by tig.2. 
The solid line depicts the biphasic secretory response 
of control islets stimulated with 300 mg glucose/l00 
ml. As evidenced by the broken line, addition of 1 mM 
quinine to the perifusate was followed by a rapid 
decline of IRI secretion rate. Upon removal of the 
drug, the rate of secretion ot only returned to con- 
trol values but reached levels significantly higher. 
3.2. Glucose metabolism 
The effect of quinine on glucose metabolism by 
islet cells, is detailed in table 2. 50 PM quinine did not 
change glucose oxidation or utilization, whereas both 
metabolic parameters were inhibited by 1 mM of the 
drug. It is of note that oxidation was more depressed 
than utilization and that 500 PM-quinine, which 
clearly inhibited IRI release (fig.l), caused only a 
minor decrease of glucose metabolism in the presence 
of 100 mg of the sugar/l00 ml (table 2). 
4. Discussion 
In cardiac muscle, the main and best established 
effect of quinine (and of its isomer) is to depress 
contractility [ 15,161, but in some conditions, low 
concentrations of the drug also produce a positive 
inotropic effect [ 171 . This latter property is compara- 
ble to the potentiation of twitch tension provoked 
by the alkaloid (lo-’ to 10e4 M) in skeletal muscle 
[181- 
The results reported here show that low concentra- 
tions of quinine slightly stimulate insulin release in 
the absence of glucose and powerfully potentiate the 
insulinotropic effect of the sugar, mostly at glucose 
levels close to the threshold for stimulation of secre- 
tion. The first observation contrasts but the second 
concurs with the effects of methylxanthines, [7], 
which, however, must be used at higher concentrations. 
Preliminary experiments indicating the Ca-dependency 
of this potentiating effect of quinine point out ano- 
ther difference between the mode of action of both 
types of alkaloids. At the present ime, the exact 
mechanism of action of quinine is not elucidated, but 
does not seen to involve changes of glucose metabo- 
lism although requiring its normal fonctioning as in- 
dicated by the experiments carried out at low tempe- 
rature. The possibility that the recorded effects of 
quinine are indirect of quinine are indirect and mediat- 
ed by stimulation of neurotransmitter release from 
cholinergic terminals in the islets is also unlikely. 
The inhibition of glucose-stimulated insulin secre- 
tion by high concentrations of quinine seems to be 
accounted for by the alteration of glucose metabolism. 
However, another mechanism cannot be ruled out 
since 0.5 mM quinine already reduced secretion with 
very little effect on metabolism. This would be in 
keeping with conclusions reached for cardiac muscle, 
where the inhibition of carbohydrate and lipid 
metabolism by quinine and quinidine [19,201 has not 
been considered as a valid or the sole explanation for 
the depressant effect of these drugs on contractility. 
In conclusion, the similarities between the effects 
of quinine on muscle cells and pancreatic P-cells rein- 
force the view that contraction and secretion share 
similar basic processes of control. Quinine might thus 
prove to be a useful tool to gain further insight in some 
steps of the stimulus-secretion coupling leading to exo- 
cytosis of various ecretory products including insulin. 
Since many effects of the alkaloid on muscle have been 
related to its ability to release Ca from intracellular 
stores or to inhibit uptake of the cation at this level 
[21,23] , quinine might help to evaluate apossible 
involvement of these pools in the secretory process. 
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